Question | 2017 Responses | 2018 Responses | OR | 95% CI for OR | P value† | |||||
n‡ | N§ | %* | n‡ | N§ | %* | Lower | Upper | |||
1. Does the MDT have TORs or guidelines to guide the conduct of the meetings? (yes) | 20 | 129 | 15.5 | 54 | 117 | 46.2 | 4.8 | 2.5 | 9.3 | <0.001 |
2. Are there established criteria for referral of patients to MDT meetings? (yes) | 34 | 129 | 26.4 | 62 | 117 | 53.0 | 2.9 | 2.0 | 4.4 | <0.001 |
3. Is there a follow-up process to check whether referrals from the MDT are actually made? (yes) | 18 | 129 | 14.0 | 22 | 117 | 18.8 | 1.6 | 0.7 | 3.5 | 0.262 |
4. Does the MDT use clinical practice guidelines/treatment protocols relevant to patients with cancer? (always or usually) | 81 | 129 | 62.8 | 72 | 117 | 61.5 | 0.9 | 0.6 | 1.3 | 0.532 |
5. Does the MDT routinely collect the time from diagnosis to definitive treatment? (yes) | 13 | 128 | 10.2 | 22 | 117 | 18.8 | 2.0 | 0.9 | 4.1 | 0.078 |
6. Are internal audits conducted to confirm that treatment decisions match current best practice? (yes) | 9 | 129 | 7.0 | 9 | 117 | 7.7 | 1.2 | 0.7 | 1.9 | 0.543 |
*Percentage of ‘positive’ responses.
†P value adjusted for team clustering.
‡Number of ‘positive’ responses.
§Total number of responses.
CI, confidence interval; MDT, multidisciplinary team; OR, odds ratio; TOR, Terms of Reference.